AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
54 hedge funds and large institutions have $29.6M invested in AVEO Pharmaceuticals, Inc. in 2015 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 15 reducing their positions, and 7 closing their positions.
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
32% more capital invested
Capital invested by funds: $22.5M → $29.6M (+$7.19M)
10% more funds holding
Funds holding: 49 → 54 (+5)
6% more call options, than puts
Call options by funds: $132K | Put options by funds: $124K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
20% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$2.86M |
| 2 |
Renaissance Technologies
New York
|
+$1.52M |
| 3 |
PC
PointState Capital
New York
|
+$1.08M |
| 4 |
Morgan Stanley
New York
|
+$263K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$225K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$861K |
| 2 |
California Public Employees Retirement System
Sacramento,
California
|
-$604K |
| 3 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$462K |
| 4 |
SIM
Spark Investment Management
New York
|
-$383K |
| 5 |
Goldman Sachs
New York
|
-$214K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Citigroup
New York
| $1K | +$648 | +36 | New |
|
52
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $2 | – | – | – |
|
|
ACP
53
Acuta Capital Partners
Redwood City,
California
| – | -$861K | -59,387 | Closed |
|
54
Jane Street
New York
| – | -$109K | -7,547 | Closed |
|
|
NCCM
55
Nine Chapters Capital Management
Short Hills,
New Jersey
| – | -$94K | -6,500 | Closed |
|
|
RFC
56
Russell Frank Company
Seattle,
Washington
| – | -$93K | -6,425 | Closed |
|
|
CCMH
57
Cornerstone Capital Management Holdings
New York
| – | -$73K | -5,010 | Closed |
|
58
D.E. Shaw & Co
New York
| – | -$50K | -3,481 | Closed |
|
|
FMA
59
FNY Managed Accounts
New York
| – | -$18.1K | -1,250 | Closed |
|
|
GC
60
Globeflex Capital
San Diego,
California
| – | -$702 | -39 | -57% |
|
61
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$432 | +24 | New |
|
AVEO Hedge Fund Activity: Q2 2015 in Review
54 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q2 2015, worth a combined $29.6M — up 32% from $22.5M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new AVEO positions and 7 closed out — a net gain of 5 holders — while 12 added to existing stakes and 15 trimmed.
The largest buyer was Cormorant Asset Management, opening a new position worth an estimated $2.86M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $861K sold.
- 54 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q2 2015, up from 49 in Q1 2015.
- Funds reported $29.6M of AVEO Pharmaceuticals, Inc. stock for Q2 2015, up 32% quarter-over-quarter.
- 12 funds opened new AVEO Pharmaceuticals, Inc. positions in Q2 2015 and 7 closed out, a net change of +5 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q2 2015 was Cormorant Asset Management, an estimated $2.86M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q2 2015 was Acuta Capital Partners, an estimated $861K sold.
Based on aggregated 13F filings for Q2 2015.